This product includes CME/CMLE as well as the 5 hours of lecture content, the lecture slides, key reference sheet, a post-course exam, and an AMP Certificate of Completion. 


Since the publication of the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues in 2008, there have been significant advances in our knowledge of the biology and genetics of hematopoietic malignancies resulting in improved diagnostic and prognostic criteria, disease classification and therapeutic strategies. The 2016 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues incorporates these advances with revisions to current entities and addition of provisional entities. This AMP certificate program will cover the major changes made in the 2016 WHO revision. Participants will learn from experts in the field covering the following topics: B lymphoid neoplasms, Peripheral T cell lymphomas, Acute Leukemias, Myeloproliferative Neoplasms, Myelodysplastic syndromes and Myelodysplastic/myeloproliferative neoplasms. An update on the clinicopathologic features and classification of hematologic malignancies will be presented providing participants with skills and knowledge to accurately diagnose and subclassify hematologic malignances according to the revised 2016 WHO criteria.

Target Audience: Practicing pathologists, oncologists, medical trainees and other healthcare professionals in the U.S. and abroad.

This certificate program was planned and coordinated by the Content Directors:

  • Jennifer Dunlap, MD, Oregon Health & Science University, Portland, OR
  • Mark D, Ewalt, MD, University of Colorado, Denver, CO

and supported by the Training & Education Committee (Cecilia C.S. Yeung, MD, Chair) 

Duration: 5 hours

Certificate Program Topics (for details about each topic, click on the “Topics” tab at the top of the page)

  • B-Lymphoid Neoplasms (Eric D. Hsi, MD)
  • Nodal Peripheral T-cell Lymphomas (Stefano A. Pileri, MD)
  • Acute Leukemias (Daniel A. Arber, MD)
  • Myeloidproliferative Neoplasms (Tracy I. George, MD)
  • MDS and MDS/MPN (Robert Hasserjian, MD)


Last day to purchase course and claim credit: January 18, 2021

Maximum CME/CMLE credit available: 5.0

The content for this certificate program was made in collaboration with Association for Molecular Pathology (AMP) and Society for Hematopathology (SH)

How to claim credit: To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey. To access the online survey, click "Submit credit" on the course homepage, or click on "My Credit" on the menu to the left.

AMA PRA Category 1 Credit(s)™

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 5.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity. 

* You may not submit SAMs and CME/CMLE credit for the same content.

You might also be interested in:


Note: Members of AMP can access this at a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Course Information
Course Date:
May 31, 2018
Introduction and Course Materials
B-Lymphoid Neoplasms (and how practice is changing)


Dr. Eric D. Hsi will review important changes to the recently published update to the 2016 WHO classification of B-cell neoplasms. Topics include monoclonal B-cell lymphocytosis, in situ follicular neoplasia, pediatric type follicular lymphoma, and provisional entities such as large B-cell lymphoma with IRF rearrangement and EBV+ mucocutaneous ulcer. The appropriate molecular characterization of diffuse large B-cell lymphomas and high grade B-cell lymphomas will also be discussed.


Learning Objectives:

1Apply new WHO 2016 criteria to the diagnosis of monoclonal B-cell lymphocytosis.

2. Distinguish in situ follicular neoplasia from follicular lymphoma.

3. Describe the pathologic features of pediatric type follicular lymphoma.

4. Design a strategy for evaluating diffuse aggressive large B-cell lymphomas.

Speaker Information
Eric D. Hsi MD   [ view bio ]
Nodal Peripheral T-cell Lymphomas


Following a brief overview on the difficulties encountered in the definition of the epidemiology, classification, diagnosis, prognosis, and therapy of peripheral T/NK-cell lymphomas, nodal peripheral T-cell lymphomas (PTCLs) will be discussed in detail. These neoplasms account for more than 60% of tumours stemming from peripheral T-lymphocytes. In the Revised WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, they correspond to 4 entities: PTCL, not otherwise specified (NOS), PTCLs related to follicular helper T-lymphocytes (FTH), ALK+ anaplastic large cell lymphoma (ALCL), and ALK- ALCL. Tumour related to TFH cells represent a new category, including angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma and neoplasms lacking the morphologic characteristics of the previous two subtypes but also stemming from TFH-elements. The latter group was in the past included among PTCLs/NOS. ALK- ALCL was promoted from provisional to accepted entity because of emerging molecular evidences. In addition, the new provisional category of breast implant-associated ALCL was included. Most of the changes introduced in the Revised WHO Classification by comparison with the 2008 fourth edition are due to the extensive application of molecular techniques, including gene expression profiling and next generation sequencing. All the changes will be highlighted and discussed.


Learning Objectives:

1. Discuss the complexity of the approach to peripheral T-cell lymphomas.

2. Explain the four categories of nodal peripheral T-cell lymphomas.

3. Identify potential targets for innovative therapies.

Speaker Information
Stefano A. Pileri MD  [ view bio ]
Acute Leukemias


Dr. Daniel A. Arber reviews the most recent revision of the World Health Organization (WHO) classification of acute leukemia with a particular focus on acute myeloid leukemia. A summary of changes to the classification of lymphoblastic leukemia/lymphoma and acute leukemias of ambiguous lineage will also be summarized.


Learning Objectives:

1. Describe genetic abnormalities that define new disease categories of acute leukemia.

2. Distinguish genetic mutations that define disease entities versus prognostic markers in acute leukemia.

3. Apply diagnostic criteria for acute leukemia using a combination of clinical information, morphology, immunophenotyping and molecular genetic testing.

Speaker Information
Daniel A. Arber MD  [ view bio ]
Myeloproliferative Neoplasms


Dr. Tracy George will discuss updates in the classification of myeloproliferative neoplasms, also including eosinophilic neoplasms with recurring mutations, and mastocytosis. This includes new criteria for accelerated phase (response-to-TKI criteria) in chronic myeloid leukemia, WHO 2016 criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis, as well as eosinophilic neoplasms with and without recurring mutations. Updates in the diagnosis of mastocytosis, now its own chapter again in the WHO 2016 classification, will also be explained.


Learning Objectives:

1. Describe provisional criteria for response-to-tyrosine kinase inhibitors in chronic myeloid leukemia

2. Discuss updated pathologic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis

3.Follow a diagnostic algorithm for eosinophilia

4. Recognize neoplastic mast cells in bone marrow

Speaker Information
Tracy I. George MD   [ view bio ]
Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms


Dr. Robert Hasserjian will review the updated diagnostic criteria of myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms according to the recently revised WHO Classification, with emphasis on significant changes from the prior (2008) WHO Classification. New and revised entities within this group of diseases will be presented and the appropriate testing required to correctly diagnose these neoplasms will be discussed.


Learning Objectives:

1. Describe the criteria for establishing a primary diagnosis of myelodysplastic syndrome.

2. Distinguish between the subtypes of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms according to current criteria in the 2016 WHO Classification.

3. Employ ancillary testing (including flow cytometry, immunohistochemistry, cytogenetics, and molecular genetic testing) effectively in the diagnosis, classification, and prognostication of myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Speaker Information
Robert Hasserjian MD  [ view bio ]
Wrap Up and Additional Materials
Individual topic purchase: Selected
American Medical Association
Continuing Medical Education: 5.00
American Society for Clinical Pathology
CMLE: 5.00
Association for Molecular Pathology
AMP Certificate Program: 5.00
AMP Regular Member: $124.00
AMP Technologist Member: $124.00
AMP Associate Member: $124.00
Non-member Price: $249.00